Samsung Biologics

Samsung Biologics

World Rank (Aug-2026)
500
Market Cap (Aug-2026)
51.514 Billion USD
World Rank (Jan-05-2024)
433
Market Cap (Jan-05-2024)
41.719 Billion USD
World Rank (Jul-30-2023)
418
Market Cap (Jul-30-2023)
43.803 Billion USD
World Rank (Jan-07-2022)
417
Market Cap (Jan-07-2022)
46.573 Billion USD
World Rank (Jan-01-2021)
318
Market Cap (Jan-01-2021)
50.610 Billion USD
Headquarters Country
South Korea
CEO
John Rim
Employee Count
2,587
Employee Count as of Date
As on 2022
World Region
Asia
World Subregion
Eastern Asia
Annual Revenue in USD
3,247 Million USD
Annual Operating Income in USD
1,475 Million USD
Annual Net Income in USD
1,272 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
7,882 Million USD
Total Liabilities in USD
2,572 Million USD
Total Equity in USD
5,310 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Pharmaceutical
Biopharmaceutical
Biotechnology
HealthCare Products
Company Website
Samsung Biolgics
Wikipedia
Wikipedia
Yahoo
Yahoo @ SouthKorea
Company Profile

Samsung Biologics is Biopharmaceutical Manufacturing Company with headquarters is in South Korea. It provides development, manufacturing , laboratory testing services at every stage for Biopharmaceutical products while meeting the evolving needs of the global healthcare industry. The company has 2,587 employees as on 2022.

Annual Results Summary

SAMSUNG BIOLOGICS - Yearly Results - Revenue and Net Profit - in Billion KRW:

Annual EndingRevenueOperating ProfitNet Profit
Dec-20223,001983798
Dec-20211,568537393
Dec-20201,164292240
Dec-201970191202
Dec-201853555224
Balance Sheet Summary

Total Assets as on Dec-2022 is 16,582 Billion KRW.

Total Liabilities as on Dec-2022 is 7,597 Billion KRW.

Total Equity as on Dec-2022 is 8,984 Billion KRW.

Founded Year
2011
Stock Exchange
South Korea

Share